NASDAQ:ADMP - Adamis Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.60 -0.18 (-6.47 %)
(As of 11/18/2018 07:23 AM ET)
Previous Close$2.60
Today's Range$2.60 - $2.78
52-Week Range$2.20 - $5.10
Volume217,621 shs
Average Volume383,867 shs
Market Capitalization$122.96 million
P/E Ratio-2.89
Dividend YieldN/A
Beta0.71
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of albuterol (APC-2000) for the treatment of bronchospasms; fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, ophthalmic preparations, topical compounds for pain, and men's and women's health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.

Receive ADMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADMP
Previous Symbol
CUSIPN/A
Phone858-997-2400

Debt

Debt-to-Equity RatioN/A
Current Ratio3.17
Quick Ratio0.54

Price-To-Earnings

Trailing P/E Ratio-2.89
Forward P/E Ratio-3.02
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.07 million
Price / Sales9.41
Cash FlowN/A
Price / CashN/A
Book Value$1.22 per share
Price / Book2.13

Profitability

EPS (Most Recent Fiscal Year)($0.90)
Net Income$-25,530,000.00
Net Margins-248.43%
Return on Equity-87.64%
Return on Assets-66.85%

Miscellaneous

Employees126
Outstanding Shares47,290,000
Market Cap$122.96 million
OptionableOptionable

Adamis Pharmaceuticals (NASDAQ:ADMP) Frequently Asked Questions

What is Adamis Pharmaceuticals' stock symbol?

Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."

How were Adamis Pharmaceuticals' earnings last quarter?

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) posted its quarterly earnings results on Friday, August, 10th. The specialty pharmaceutical company reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.10. The specialty pharmaceutical company earned $3.92 million during the quarter, compared to the consensus estimate of $4.14 million. Adamis Pharmaceuticals had a negative return on equity of 87.64% and a negative net margin of 248.43%. View Adamis Pharmaceuticals' Earnings History.

When is Adamis Pharmaceuticals' next earnings date?

Adamis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for Adamis Pharmaceuticals.

What price target have analysts set for ADMP?

4 brokerages have issued 12-month price objectives for Adamis Pharmaceuticals' shares. Their forecasts range from $2.50 to $13.00. On average, they anticipate Adamis Pharmaceuticals' share price to reach $7.3750 in the next twelve months. This suggests a possible upside of 183.7% from the stock's current price. View Analyst Price Targets for Adamis Pharmaceuticals.

What is the consensus analysts' recommendation for Adamis Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adamis Pharmaceuticals.

What are Wall Street analysts saying about Adamis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Adamis Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned subsidiaries, Adamis Labs and Adamis Viral Therapies. Adamis Labs is a commercial stage specialty pharmaceutical company targeting high-prescribing physicians in the allergy, respiratory and pediatric medicine market segments. To complement and add to the sales efforts of Adamis Labs, Adamis Viral Therapies is focused on the development of patented, highly-valued proprietary vaccine technology that Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis. Adamis also provides packaging for pharmaceutical and nutraceutical products. The company is headquartered in Del Mar, California. " (11/15/2018)
  • 2. Maxim Group analysts commented, "The PDUFA date for Symjepi jr. (0.15mg) is approaching on 9/27/18, we expect a positive response from the FDA. Symjepi (0.3mg & 0.15mg) is partnered to Sandoz-Novartis (NVS – NR). Our expectation is that Sandoz will launch both Symjepi products sometime in the second half following low-dose approval (though precise timing has not been announced)." (9/12/2018)
  • 3. HC Wainwright analysts commented, "EpiPen as an Exchange NASDAQ Value (M) $65.4 Market Cap (M) $101 Shares Outstanding (M) 45.1 3 Interest (M) 3.55 Cash (M) $37.9 Total Debt (M) $2.3 Cash balances and share count are projected based on 3Q18 capital raise." (8/23/2018)

Has Adamis Pharmaceuticals been receiving favorable news coverage?

News headlines about ADMP stock have trended somewhat negative recently, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Adamis Pharmaceuticals earned a news sentiment score of -1.2 on InfoTrie's scale. They also assigned media coverage about the specialty pharmaceutical company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an effect on the stock's share price in the near future.

Who are some of Adamis Pharmaceuticals' key competitors?

Who are Adamis Pharmaceuticals' key executives?

Adamis Pharmaceuticals' management team includes the folowing people:
  • Mr. Richard C. Williams, Chairman & Consultant (Age 74)
  • Dr. Dennis J. Carlo, Pres, CEO & Director (Age 75)
  • Mr. Robert O. Hopkins, VP of Fin., CFO & Sec. (Age 58)
  • Mr. David J. Marguglio, Sr. VP, Chief Bus. Officer & Director (Age 48)
  • Mr. Robert B. Rothermel, Consultant & Director (Age 74)

Who are Adamis Pharmaceuticals' major shareholders?

Adamis Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include First Manhattan Co. (7.23%), DekaBank Deutsche Girozentrale (2.54%), BlackRock Inc. (1.88%), Perceptive Advisors LLC (0.29%), Leisure Capital Management (0.26%) and Acropolis Investment Management LLC (0.06%). View Institutional Ownership Trends for Adamis Pharmaceuticals.

Which major investors are selling Adamis Pharmaceuticals stock?

ADMP stock was sold by a variety of institutional investors in the last quarter, including Leisure Capital Management. View Insider Buying and Selling for Adamis Pharmaceuticals.

Which major investors are buying Adamis Pharmaceuticals stock?

ADMP stock was purchased by a variety of institutional investors in the last quarter, including First Manhattan Co., BlackRock Inc., DekaBank Deutsche Girozentrale, Perceptive Advisors LLC and Acropolis Investment Management LLC. View Insider Buying and Selling for Adamis Pharmaceuticals.

How do I buy shares of Adamis Pharmaceuticals?

Shares of ADMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adamis Pharmaceuticals' stock price today?

One share of ADMP stock can currently be purchased for approximately $2.60.

How big of a company is Adamis Pharmaceuticals?

Adamis Pharmaceuticals has a market capitalization of $122.96 million and generates $13.07 million in revenue each year. The specialty pharmaceutical company earns $-25,530,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Adamis Pharmaceuticals employs 126 workers across the globe.

What is Adamis Pharmaceuticals' official website?

The official website for Adamis Pharmaceuticals is http://www.adamispharmaceuticals.com.

How can I contact Adamis Pharmaceuticals?

Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-997-2400 or via email at [email protected]


MarketBeat Community Rating for Adamis Pharmaceuticals (NASDAQ ADMP)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  232 (Vote Outperform)
Underperform Votes:  122 (Vote Underperform)
Total Votes:  354
MarketBeat's community ratings are surveys of what our community members think about Adamis Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel